Competing interests
SE, mitochondrial dysfunction, epilepsy
MITOCHONDRIAL DYSFUNCTION, DISORDERS, EPILEPSY
DEB has received speaker fees, conference attendance support or advisory board fees from Baxter, Cardinal Health and Avanos. ZP has received honoraria for consultancy from GlaxoSmithKline, Lyric Pharmaceuticals, Faraday Pharmaceuticals and Fresenius-Kabi, educational support from Baxter and Nestle Health Science and speaker fees from Orion, Baxter, Sedana, Fresenius-Kabi and Nestle. HM holds patents relating to intravenous hydration and to regulation of metabolic efficiency using renin-angiotensin system antagonists. SE and SJH hold patents with Vitaflo International Ltd for compositions different from that used in this study, for treating/ dietary management of drug resistant epilepsy and disorders associated with mitochondrial dysfunction, and also are in receipt of grant funding from Vitaflo International Ltd (not connected with this study). AL has received honorarium from Baxter for speaker fees. A patent has been submitted for the ketogenic feed regime used in this study (ZAP, AM, AL, DB). Vitaflo International Ltd were involved in initial discussions about the study and provided the K.Quik® component for the ketogenic feed gratis. Neither Vitaflo International Ltd nor Nestle Health Sciences contributed to study design, study implementation, data analysis or interpretation. Other authors declare no competing interests.